Rosiglitazone increases PPARγ in renal tubular epithelial cells and protects against damage by hydrogen peroxide

American Journal of Nephrology

Volumn 27, Issue 4, 2007, Pages 425-434

  Sommer, Manfred ^a   Wolf, Gunter ^a,b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Cell damage; Oxidative stress; PPAR ; Renal tubular cells; Rosiglitazone

Indexed keywords

CYCLOHEXIMIDE; DACTINOMYCIN; DNA FRAGMENT; HYDROGEN PEROXIDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; THYMIDINE; TRITIUM; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; EPITHELIUM CELL; GEL MOBILITY SHIFT ASSAY; IMMUNOFLUORESCENCE; KIDNEY TUBULE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CATTLE; CELL CULTURE; DRUG EFFECT; GENE EXPRESSION; GIEMSA STAIN; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; AZURE STAINS; CATTLE; CELL PROLIFERATION; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPITHELIAL CELLS; GENE EXPRESSION; HYDROGEN PEROXIDE; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULES; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 34447545820     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000105125     Document Type: Article

References (34)

1. Juge-Aubry C, Pernin A, Favez T, Burger AG, Wahli W, Meier CA, Desvergne B: DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferators response elements. J Biol Chem 1997;272:25252-25259.
2. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 2000;405:421-424.
3. Guan J: Peroxisome proliferator-activated receptor family and its relationship to renal complication of the metabolic syndrome. J Am Soc Nephrol 2004;15:2801-2815.
4. Chana RS, Lewington AJ, Brunskill NJ: Differential effects of peroxisome proliferator-activated receptor-γ ligands in proximal tubular cells. Kidney Int 2004;65:2081-2090.
5. Rangwala SM, Lazar MA: Peroxisome proliferator-activated receptor-γ in diabetes and metabolism. Trends Pharmacol Sci 2004;25:331-336.
6. Ma LJ, Marcantoni C, Linton MRF, Fazio S, Fogo AB: Peroxisome proliferators-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001;592:1899-1910.
7. Jiang C, Ting AT, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
8. Matsuyama M, Yoshimura R, Hase T, Uchida J, Tsuchida K, Takemoto Y, Kawahio Y, Sano H, Nakatani T: Expression of peroxisome proliferator-activated receptor-γ in renal ischemia-reperfusion injury. Transplant Proc 2005;37:1684-1685.
9. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC: Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998;47:1326-1334.
10. Yang H-C, Ma L-J, Ma J, Fogo AB: Peroxisome proliferators-activated receptor-γ agonists is protective in podocyte injury-associated sclerosis. Kidney Int 2006;69:1756-1764.
11. Tang SCW, Leung JCK, Chan LYY, Tsang AWL, Lai KN: Activation of tubular epithelial cells in diabetic nephropathy and the role of peroxisome proliferator-activated receptor-γ agonist. J Am Soc Nephrol 2006;17:1633-1681.
12. Sommer M, Eismann, Gerth J, Stein G: Interleukin 4 co-stimulates the PDGF-BB and bFGF-mediated proliferation of mesangial cells and myofibroblasts. Nephron 2002;92:868-882.
13. Sommer M, Gerth J, Stein G, Wolf G: Transdifferentiation of endothelial and renal tubular epithelial cells into myofibroblast-like cells under in vitro conditions: a morphological analysis. Cells Tissues Organs 2005;180:204-214.
14. Lutfalla G, Uze G: Performing quantitative reverse-transcribed polymerase chain reaction experiments. Methods Enzymol 2006;410:386-400.
15. Kuntzen C, Sonuc N, De Toni EN, Oplez C, Mucha SR, Gerbes AL, Eichhorst ST: Inhibition of c-Jun-N-terminal-kinase sensitizer tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res 2005;65:6780-6788.
16. Siegel MR, Sisler HD: Inhibition of protein synthesis in vitro by cycloheximide. Nature 1963;200:675-676.
17. Srafidis PA, Bakris GL: Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006;70:1223-1233.
18. Zafiriou S, Stanners SR, Polhill TS, Poronnik P, Polllock CA: Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses. Kidney Int 2004;65:1647-1653.
19. Wolf G: Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 2007 (in press) .
20. Shah SV, Baliga R, Rajapurkar M, Fonseca VA: Oxidants in chronic kidney disease. J Am Soc Nephrol 2007;18:16-28.
21. Wardle EN: Cellular oxidative processes in relation to renal disease. Am J Nephrol 2005;25:13-22.
22. Salshudseen AK, Clark EC, Nath KA: Hydrogen-peroxide-induced renal injury. J Clin Invest 1991;88:1886-1893.
23. Sakai M, Tsukada T, Harris RC: Oxidant stress activates AP-1 and heparin-biding epidermal growth factor-like growth factor transcription in renal epithelial cells. Exp Nephrol 2001;9:28-39.
24. Arany I, Megyesi JK, Nelkin BD, Safirstein RL: STAT3 attenuates EGFR-mediated ERK activation and cell survival during oxidant stress in mouse proximal tubular cells. Kidney Int 2006;70:669-674.
25. Bader N, Grune T: Protein oxidation and proteolysis. Biol Chem 2006;387:1351-1355.
26. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Polllock CA: Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 2005;16:638-645.
27. Ghosh SS, Gehr TW, Ghosh S, Fakhry I, Sica DA, Lyall V, Schoolwerth AC: PPARγ ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 2003;64:52-62.
28. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Park SK: Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 2006;21:2096-2105.
29. Wolf G, Neilson EG: Cellular biology of tubulointerstitial growth. Curr Top Pathol 1995;88:69-97.
30. Morigi M, Benigni A, Remuzzi G, Imberti B: The regenerative potential of stem cells in acute renal failure. Cell Transplant. 2006;15(suppl 1):S111-117.
31. Lin F: Stem cells in kidney regeneration following acute renal injury. Pediatr Res 2006;59:74R-78R.
32. Hishikawa K, Fujita T: Stem cells and kidney disease. Hypertens Res 2006;29:745-749.
33. Sivarajah A, Chatterjee PK, Patal NSA, Todorovic Z, Hattori Y, Brown PAJ, Stewart KN, Helder M-F, Cuzzocrea S, Thiemermann C: Agonists of peroxisome proliferator-activated receptor-γ reduce renal ischemia/reperfusion injury. Am J Nephrol 2003;23:267-276.
34. Walker PD, Shah SV: Hydrogen peroxide cytotoxicity in LLC-PK1 cells: a role for iron. Kidney Int 1991;40:891-898.